Crisaborole is a topical active pharmaceutical ingredient and reference standard for quality control of this first-in-class boron-based PDE4 inhibitor. The synthesis of Crisaborole involves reaction of 4-halogenated benzonitrile with benzo[c][1,2]oxaborole-1,5(3H)-diol under basic conditions in an organic solvent, yielding the product in high purity . In quality control contexts, Crisaborole and its related impurities are essential analytical reference standards for impurity profiling and method development. As a topical ointment, Crisaborole is indicated for mild-to-moderate atopic dermatitis in patients 2 years of age and older .
|
Parameter |
Specification |
|
Product Name |
Crisaborole |
|
CAS Number |
906673-24-3 |
|
Molecular Formula |
C₁₄H₁₀BNO₃ |
|
Molecular Weight |
251.05 g/mol |
|
Appearance |
Solid |
|
Storage Condition |
Room temperature (20–25°C) per FDA label for ointment |
Crisaborole (AN2728) shows potent activity both in vivo and in vitro. The anti-inflammatory properties of AN2728 are under research. It is also used as a pharmaceutical intermediate.
The biggest advantage of Crisaborole is that it is a small-molecule non-hormonal drug that can combine both therapeutic effect and comfort. For some patients, it even has almost no side effects. It is the first topical dermatological drug to be included in the list of new drugs urgently needed in clinical practice. The launch of Crisaborole has filled the treatment demand for atopic dermatitis in children and adults in China, breaking the status quo that there had been no new products in the field of topical non-hormonal anti-inflammatory therapy for more than 10 years, which is of epoch-making significance.
Crisaborole (AN2728) is a selective small-molecule PDE4 inhibitor with broad-spectrum anti-inflammatory activity.
Contact Cosperpharm for Crisaborole inquiries related to your topical PDE4 inhibitor program.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
